Precision For Medicine

Multi-omics and AI are everywhere. But what happens *after* the hype? On December 3 at 10:30 AM EST, join leading voices from Precision for Medicine, SOPHiA GENETICS and OLINK for a conversation that finds the signal through the noise. We’ll explore ways to move forward with the markers that truly make a difference. Expect clarity, actionable insights, and strategies you can put to work immediately. Reserve your spot today: https://lnkd.in/eHjBjKf6

Impact outcomes no matter where you work. Remote Financial Analysts wanted. Senior Financial Analyst: https://lnkd.in/e_MTsYzb Principal Financial Analyst: https://lnkd.in/eiUkDyCp

From advanced biomarker strategies to innovative trial designs, overcome the challenges of hematologic malignancies with a trusted partner. Connect with our experts at ASH Booth 671. Equip your program with the insight, expertise, and resources to accelerate progress toward approval. #ASH2025

Every “omics” buzzword promises meaning. Few deliver it. Behind the hype lies a messy, fragmented world where disconnected systems stall decisions, consume samples, and leave sponsors stranded between signal and noise. Samples get wasted, progress stalls, and decisions are delayed. With finite samples that are often destroyed during analysis, you can’t afford to lose meaning in translation. Our experts are fluent in every biological language, helping sponsors unify fragmented platforms, translate data into insight, and ensure every decision counts. https://lnkd.in/eJ6V5s4U

Biospecimen & Biomarker Operations teams – how are you keeping track of the priceless samples and derivatives you’re collecting from patients in precision medicine clinical trials? Get a 360° view of clinical samples across the entire precision medicine lifecycle, from collection through long-term storage. Learn more about Precision QuartzBio’s Sample Intelligence solution, powered by the first ensemble of Precision Medicine AI Agents. https://lnkd.in/eMjVhAJH?

Thank you to everyone who joined Precision for Medicine in Shanghai last week at #ChinaTrials17! We want to extend special thanks to those that attended our panel “Navigating Global Trials in Oncology & Rare Diseases: Insights from Former FDA Oncology Director, CRO, and Biopharmas on Global Regulatory Strategies.” We deeply appreciate the support and participation of our guest panelists Bin Yang, Hua Ye, and Helen Jiang along with our Precision panelists Jing Ping Yeo, Harpreet Singh, MD, and John McIntyre, PhD. To our sponsor partners, colleagues, and new connections… thank you! To learn more about Precision’s clinical services in the Asia-Pacific region or to connect with one of our team members, please visit: https://lnkd.in/e4fRkkir #ClinicalTrials #Oncology #RareDiseases #DrugDevelopment #GlobalHealth #Innovation

New whitepaper: Moving ADCs to the Front Line: Perspectives from FDA Oncology Experts Moving ADCs into a frontline setting is a true measure of success and can lead to a potential blockbuster asset. Harpreet Singh, MD and Nicholas Richardson, DO, MPH have combined their insights from their time in the FDA and beyond, into a whitepaper that includes: -Case studies on successfully moving ADCs into frontline settings -Keys to gaining accelerated approval based on single-arm studies -The importance of early studies in managing toxicities Watch the preview video with Harpreet, then visit instituteatprecision.com to download the whitepaper.

We are excited to be participating at PHUSE SDE this week in Bengaluru. Join our very own Rajesh Kumar Arumugam as he will be introducing how the AI-DGI model is structured and the approach to overcome barriers in applying AI to oncology.

We are pleased to welcome Marta Imbert as Senior Vice President, Clinical Monitoring. Marta brings over two decades of CRO expertise and leadership supporting full-service and functional service provider (FSP) models. Most recently, she served as Vice President and Head of EMEA Clinical Solutions at PRA/ICON, following a fifteen year tenure at IQVIA where she served as the Oversight Lead for two major global clinical full-service models plus leadership roles in Clinical FSP. Marta’s proficiency in leading high-performing teams and developing innovative clinical strategies, combined with her robust customer management skills in full-service provider environments, allows her to offer innovative, customized solutions for sponsors. In her new role she will focus on high quality and timely delivery expanding our current strengths to larger studies and a more diversified geographical footprint. She will lead teams to embrace changes in systems and processes while fostering close alignment between CTMs and Clinical operations staff. Congratulations and welcome to Precision, Marta!

Heading to the Jefferies London Healthcare Conference? Don't miss your chance to meet our team and discuss innovation, growth strategies, and the non-stop changes impacting healthcare and drug development. Whether you’re interested in exploring potential partnerships or learning more about our approach, reach out to schedule a meeting and we’d be happy to connect.